Derma Sciences, Inc. (DSCI) Cotización

The bid $6.90 support is ridiculous here..... over 5 million dollars in bid support at $6.90

I like her here

DSCI rated outperform. Good entry point right here.

7:16AM Derma Sciences sees 2013 revenue of approx $79.7 mln, Capital IQ consensus $85 mln; co sees 2014 revenue of approx $92 mln, Capital IQ consensus $94.1 mln (DSCI) 12.36 : Co announced that total revenue for the full year ended December 31, 2013 is expected to be $79.7 million, up 7.7% compared with 2012. Advanced wound care (AWC) revenue for the fourth quarter of 2013 is expected to be $9.4 million, up 22.5% compared with the fourth quarter of 2012, and full year 2013 AWC revenue is expected to be $33.9 million, up 36.6% compared with 2012. Derma Sciences expects to report 2013 full financial results on March 14, 2014.

The Company expects 2014 total revenue to increase approximately 15.5% to $92 million, driven primarily by the continued organic AWC revenue growth for the year of 30% to 40%.

9:20AM Derma Sciences enters the skin substitute market with licensing agreement for innovative amniotic membrane wound care products (DSCI) 11.81 :

Co announces it has licensed exclusive rights to two novel human placental-derived tissue products for all dermal indications in the advanced wound care and burn markets from BioD LLC, a privately held company based in Memphis, Tenn. These products will be branded as AmnioMatrix and launched during the third quarter of 2014, expanding Derma Sciences' portfolio of advanced wound care products into the $500 million skin substitute market.
Terms of the license include an upfront cash payment, royalties on product sales and performance-based milestones to be paid in cash and Derma Sciences stock options. In support of the pending product launches, Derma Sciences plans to add approximately 12 direct sales representatives, increasing its number to 50. Along with these new representatives, the company will be adding an additional Regional Manager, Clinical Field Specialist and Total Contact Casting Specialist.
The company will also be expanding its marketing department by hiring a Product Director, Reimbursement/Healthcare Economics Director and Training and Education Director. This brings the total sales and marketing infrastructure in the U.S. to 86. The new personnel are expected to be hired before the company's global sales meeting in mid-February.

7:31AM Derma Sciences announces published research concluded total contact casting is more effective in healing diabetic foot ulcers than other standards of care (DSCI) 13.29 : Co announced that a study published in The Cochrane Collaboration concluded that non-removable, pressure-relieving casts, or total contact casts (TCC), are more effective in healing diabetes-related plantar foot ulcers than removable casts or dressings alone. Derma Sciences is the leading manufacturer and marketer of total contact casting systems, including the technologically innovative TCC-EZ. The Cochrane Collaboration is a group of more than 28,000 healthcare specialists who systematically review randomized trials of the effects of prevention, treatment and rehabilitation as well as health systems interventions.

7:17AM Derma Sciences reports results from DSC127 pharmacokinetic study; DSC127 was not detected in any subject's serum samples at any time point (DSCI) 13.29 : Co announced that all data from the pharmacokinetic (PK) study with 0.03% DSC127 gel has been collected and analyzed. Subjects topically applied 0.03% DSC127 to the wound once each day for 28 days. The mean ulcer area at baseline was 9.5 cm2 (Standard Deviation 11.9 cm2). DSC127 was not detected in any subject's serum samples at any time point, using an assay with a lower limit of quantitation of 0.200ng/mL. Accordingly, no PK parameters could be calculated. All samples were also considered to be non-reactive in an assay for anti-drug antibodies. Study subjects showed no clinically significant changes in clinical chemistry, hematology, and electrocardiograms. The 0.03% DSC127 gel was well tolerated and there were no adverse events or serious adverse events considered related to the study drug, as determined by the Principal Investigator. None of the wounds treated with DSC127 gel deteriorated.

7:30AM Derma Sciences on track to begin phase 3 program with DSC127 in December following meeting with FDA (DSCI) 11.50 : Co reported that based on a meeting held last week with the FDA, the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers. The FDA has expressed concurrence with the Company's Chemistry, Manufacturing and Controls program.

7:30AM Derma Sciences acquires global long-term exclusive rights to NIMBUS technology from Quick-Med Technologies (DSCI) 10.09 : Co and Quick-Med Technologies, a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announce the signing of an agreement whereby Quick-Med Technologies has granted Derma Sciences an exclusive global license to intellectual property related to the novel NIMBUS antimicrobial technology. Under the terms of the agreement, DSCI will make a $1.3 million upfront payment to Quick-Med Technologies and future milestone payments based on sales of products incorporating the licensed technology. In addition, the royalty paid by Derma Sciences to Quick-Med Technologies on such products will be lowered from 20% currently, to a sliding scale starting at 8.5% and declining as sales milestones are achieved.

You did a great job and no need. Most of the boards have a few lines of text and some a link or two. In other words.. If it ain't broke...

Hi everybody. Looking good now. No mod since I did the iBox?

~ Monday! $DSCI ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $DSCI ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=DSCI&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=DSCI&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=DSCI
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=DSCI#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=DSCI+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=DSCI
Finviz: http://finviz.com/quote.ashx?t=DSCI
~ BusyStock: http://busystock.com/i.php?s=DSCI&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=DSCI >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Derma Sciences meeting with FDA supports initiation of phase 3 studies with DSC127 in diabetic foot ulcers (DSCI) 8.86 : Co announced that it has discussed the results of the Company's Phase 2 clinical study of the investigational drug DSC127 for the treatment of diabetic foot ulcers with the FDA, and that the FDA has agreed that the drug's development program to date supports the initiation of Phase 3 pivotal clinical studies. Derma Sciences has received guidance from the FDA on the design of Phase 3 trials and other clinical activities, which will allow the Company to adjust the sequence of planned studies, including toxicology studies, for potentially more cost-effective and efficient Phase 3 trials than had previously been contemplated. Initiation of the Phase 3 clinical trials is expected in the second half of 2012.

http://www.sec.gov/Archives/edgar/data/806085/000090951812000032/mm02-0812derma_sc13g.htm

11-11-11 Conference call is coming up.
http://ih.advfn.com/p.php?pid=nmona&article=49791525

DSCI to Present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15, 2011 at 3:00 p.m. ET. The conference is being held September 15-16, 2011 at the Pierre Hotel in New York City. Edward J. Quilty, Chairman and CEO, will deliver the Company's corporate presentation.

11-04-2011 http://ih.advfn.com/p.php?pid=nmona&article=49812001

CompanyUpdate & 3rd Quarter ConferenceCall 11-11-11:

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on November 11, 2011 to discuss the financial results for the third quarter ended September 30, 2011. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

http://ih.advfn.com/p.php?pid=nmona&article=49791525

I agree.

THE best wound care product you can buy. I picked up 3 extra tubes of this just to keep with our emergency/GOOD "bag". This could easily be a household name/product one day!

DSCI

Derma Sciences Launches MEDIHONEY® Gel at the Fall Symposium on Advanced Wound Care 2011


http://www.ir.dermasciences.com/View.asp?b=1109&ID=47994&m=rl&I=512383

Studies demonstrate the benefit of BIOGUARD over Kerlix® AMD when used with some commonly used wound treatments:

http://ih.advfn.com/p.php?pid=nmona&article=49492847

Chart:

Jefferies 2011 Global Healthcare Conference
http://ih.advfn.com/p.php?pid=nmona&article=49304272

The presentation will be webcast live at http://wsw.com/webcast/jeff62/dsci/ and on the Investor Relations section of the Company's website at www.dermasciences.com, where it will also be archived for 90 days.

Derma Sciences to Present at the Rodman & Renshaw 13th Annual Global Investment Conference

The presentation will be webcast live at http://www.wsw.com/webcast/rrshq20/dsci and on the Investor Relations section of the Company's website at www.dermasciences.com, where it will also be archived for 90 days.

http://www.ir.dermasciences.com/View.asp?b=1109&ID=47156&m=rl&I=512383

Thanks! Glad to be able to help out =D

The Moderators on this board are being responsible & custodial for personal reasons (experience & belief in DSCI products) at this time and have not purchased this stock for trading.

Welcome 42Degrees as Assistant Moderator!

I can also personally attest that Medihoney was able to repair a 4th degree episiotomy wound in DAYS, when all other attempts failed for weeks. I promise you this product does EXACTLY what it claims it does and according to the wound specialists in our area nothing even comes close! SOLID product!

GL DSCI

Everything is way on track here.

Derma Sciences Reports Second Quarter Operating Results:
http://ih.advfn.com/p.php?pid=nmona&article=48848327

Derma Sciences today is in the strongest position in the Company’s history, both from a financial and operational perspective.
http://ih.advfn.com/p.php?pid=nmona&article=48848327

10-Q / Conference Call August 16th 2011:
http://www.ir.dermasciences.com/View.asp?b=1109&ID=46663&m=rl&I=512383

Derma Sciences has achieved a key MEDIHONEY® sales milestonehttp://ih.advfn.com/p.php?pid=nmona&article=48738061

"Eight videos including Derma Sciences Commitment to Advanced Wound Care, as well as videos about the Company’s leading products; MEDIHONEY®, XTRASORB®, BIOGUARD®, and ALGICELL® Ag".
http://ih.advfn.com/p.php?pid=nmona&article=48659746

MEDIHONEY Hydrogel dressing will be the first in the line that is directed to the treatment of burns
http://www.ir.dermasciences.com/View.asp?b=1109&ID=46444&m=rl&I=512383

Drug Administration 510(k) clearance for its patented MEDIHONEY® Hydrogel Wound and Burn Dressing with Leptospermum (Manuka) honey.
http://www.ir.dermasciences.com/View.asp?b=1109&ID=46444&m=rl&I=512383

MEDIHONEY®, XTRASORB®, BIOGUARD® and ALGICELL® Ag. These products, along with other advanced wound care products, have exhibited strong growth potential and carry higher average gross profit margins than our overall business.
http://ih.advfn.com/p.php?pid=nmona&article=48540954

If you like reading [a prospectus] Have at it here:
July 22nd:
http://ih.advfn.com/p.php?pid=nmona&article=48540954

BIOGUARD [Barrier Dressings] gets a big nod:
July 20th PR above:
http://ih.advfn.com/p.php?pid=nmona&article=48506376

Chart looks good for a step uP.

Ok skipper66. DSCI will be right here for a long while.

Poemstone, can't reply privately.

Thanks for the invite to help with the board, but I decline. I don't really want to spend too much time on these things. I have only two stocks I follow (and believe in). I am not a day trader roaming through boards all day long.

Good to know you have personal evidence how good DSCI's products work.

I truly believe this is a small great company which found itself a huge gap to fill. I own 15000 shares (=0.1% of the fully diluted share (15,281,476 = 6634187 + 3360932 + 3524239 + 1762118; Shares as per SEC filing 31.03.2011 (incl 3,360,932 shares reserved for future issuance) plus 3,524,239 shares of private placement June 2011, plus 1,762,118 warrants @ USD 9.90 for 5 year period)).

I will keep posting, if there is a good reason to do so. Please remove the post once you've read it.

Cheers, skipper

Hi skipper66. I agree with you. DSCI has been holding its own even while the broader market has had troubles.

Not too many seem to follow DSCI (yet).

I started to buy in Jan. 2007, and my last buy was in Jan. 2011.

I like the latest analyst upgrade, but I think it was too modest. Even without DSC127 they would be a very profitable company longterm. With it, I believe it could go into several billion USD in market cap, not today or tomorrow, but in the next 5-10 years.

Now they have all the financing they need in place to bring DSC127 through phase 3; no partners needed! Once that is done, it can hit the market straight away, as DSCI has a sales network in place.

The share price should go to triple digits before 2015; assuming all pans out.

DSCI is acting like a $10 stock & doing just fine.

Raised 29 million in Private Placement.
Pr June 20.

DSCI. The url's on the iBox are now enabled to open a new window. That leaves the page you start with, intact. Stone

Investor Presentation has it all.
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=2776

Employees: 195. Employee growth: 12.1%. Year 2010.
http://www.answers.com/topic/derma-sciences-inc

Read the iBox. Derma Sciences has wonderful products.